Analyst Research Report Snapshot

Title:

PLETHORA SOLUTIONS HOLDINGS - INTO PHASE III

Price:

$10.00

Provider:

Edison Investment Research

Date:

30 Oct 2007

Pages:

1

Type:

AcrobatPDF

Companies referenced:

PLE.L

Available for Immediate Download
Summary:

One of Plethora’s most important near-term value drivers, PSD502, has entered Phase III for the treatment of premature ejaculation (PE). Depending on the extent of the delay to Johnson & Johnson’s dapoxetine, PSD502 could become the first prescription product to be approved for PE, and could be launched at the end of 2009. FOR MORE INFORMATION ON ATTACHED RESEARCH PLEASE CALL 020 7190 1755 OR EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.